Search results
Showing 7321 to 7335 of 8314 results
October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.
Process manual for the endorsement of guidance and quality standard support resources (PMG29)
The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.
Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.
The MAGEC system for spinal lengthening in children with scoliosis (MTG18)
August 2024: Following the lifting on the UK suspension of MAGEC system (modified MAGEC X system), NICE's prioritisation board will be reviewing the guidance that was withdrawn in April 2020. We will update this page once a decision is made.
In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. However the guidance review in 2022 recommended it be withdrawn because it was determined that: The existing medical technologies guidance was considered along with other interventions in the update of NICE's guideline on atrial fibrillation. See evidence review A and evidence review B providing the best advice to the NHS about its use. As evident in NICE's guideline on atrial fibrillation, the evidence base and experts’ advice, the landscape for opportunistically detecting atrial fibrillation in primary care has changed significantly since the original guidance, with a wider range of devices for detecting atrial fibrillation now available.
The recommendations in this guideline on weight management during pregnancy have been updated and replaced by NICE's guideline on maternal and child nutrition (NG247). The recommendations on weight management before and after pregnancy have been updated and replaced by NICE’s guideline on overweight and obesity management (NG246).
Four commonly used methods to increase physical activity (PH2)
This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines: Walking and cycling (2012) PH41 Physical activity: brief advice for adults in primary care (2013) PH44 Exercise referral schemes to promote physical activity (2014) PH54
January 2025: This quality standard has been stood down. Quality statements on maternal and child nutrition can be found in the NICE quality standards on antenatal care and postnatal care.
This guideline has been updated and replaced by NICE guideline NG101.
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101.
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101.
Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)
This guideline has been updated and replaced by NICE guideline NG101.
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)
This guidance has been updated and replaced by NICE technology appraisal guidance 527.
myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
This advice has been updated and replaced by NICE medical technologies guidance 68.